Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib in HER2+ Gastrointestinal Cancers
NCT04430738Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of tucatinib in colorectal carcinoma (CRC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 3 more, sponsored by Pfizer. Primary endpoints: Number of Participants With Renal Dose-Limiting Toxicities at 42 days and Number of Participants With Treatment Emergent Adverse Events at 20.7 months. Started Sep 2020; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
colorectal carcinoma (CRC)gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04430738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430738.